Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00017992
- Locations
- 🇺🇸
USC School of Medicine / LA County Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami, Miami, Florida, United States
🇲🇽Instituto Mexicano de Investigacion Clinica, Col Roma, Mexico
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT00002230
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
A Study of Efavirenz in Combination With Stavudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002225
- Locations
- 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸North Shore AIDS Hosp / Division of Infectious Disease, Manhassett, New York, United States
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00002386
- Locations
- 🇺🇸
Riley Hosp for Children, Indianapolis, Indiana, United States
🇺🇸Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT00002430
- Locations
- 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸Tower ID Med Associates, Los Angeles, California, United States
🇺🇸AIDS Community Research Consortium, Redwood City, California, United States
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 186
- Registration Number
- NCT00002424
- Locations
- 🇺🇸
UCLA School of Medicine / Ctr for Research and Education, Los Angeles, California, United States
🇺🇸Associates in Research, Fort Myers, Florida, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 32
- Registration Number
- NCT00000865
- Locations
- 🇺🇸
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002308
- Locations
- 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.